Last reviewed · How we verify
Mucopolysaccharidosis, MPS-VII
Approved treatments
- Mepsevii · Ultragenyx Pharm Inc
Mepsevii works by replacing the deficient enzyme beta-glucuronidase in patients with MPS-VII. - MEPSEVII · ULTRAGENYX PHARM INC
- Mepsevii · Ultragenyx Pharmaceutical Inc
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Mucopolysaccharidosis, MPS-VII patent landscape — cliff calendar, originator estates, attackable patents
- Mucopolysaccharidosis, MPS-VII treatment landscape brief
- Mucopolysaccharidosis, MPS-VII treatment updates RSS
Frequently asked questions about Mucopolysaccharidosis, MPS-VII
What drugs treat Mucopolysaccharidosis, MPS-VII?
Tracked treatments include Mepsevii, MEPSEVII.
What is the treatment for Mucopolysaccharidosis, MPS-VII?
Standard treatment for Mucopolysaccharidosis, MPS-VII includes Mepsevii, MEPSEVII. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Mucopolysaccharidosis, MPS-VII patent cliff · Mucopolysaccharidosis, MPS-VII CI report
- Treatment: Mepsevii · Ultragenyx Pharm Inc
- Treatment: MEPSEVII · ULTRAGENYX PHARM INC
- Treatment: Mepsevii · Ultragenyx Pharmaceutical Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing